FindTrial
Sign In

Phase III study of SUN Y7017 (memantine hydrochloride) in patients with moderately severe to severe dementia of the Alzheimer's type

Phase III study of SUN Y7017 (memantine hydrochloride) in patients with moderately severe to severe dementia of the Alzheimer's type

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220078
Enrollment
Unknown
Registered
2005-09-08
Start date
2005-09-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

moderately severe to severe dementia of the Alzheimer's type

Interventions

investigational material(s) Generic name etc : SUN Y7017 INN of investigational material : memantine Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administra

Sponsors

DAIICHISANKYO Co.,Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients whose age is 50 or higher and with a probable diagnosis of moderately severe to severe dementia of the Alzheimer's type according to the diagnostic criteria

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy, Safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026